A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)

被引：0

作者：

Planchard, D. ^{[1
]}

Yang, J. C-H. ^{[2
]}

Brahmer, J. R. ^{[3
]}

Ragone, A. ^{[4
]}

Chen, J. ^{[5
,8
]}

Liu, F. ^{[6
]}

Saggese, M. ^{[7
]}

机构：

[1] Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France

[2] Natl Taiwan Univ, Dept Med Oncol, Ctr Canc, Taipei, Taiwan

[3] Johns Hopkins Univ, Baltimore, MD USA

[4] AstraZeneca Pharmaceut LP, Late Dev, Oncol R&D, Mississauga, AB, Canada

[5] AstraZeneca Pharmaceut LP, Oncol R&D, Late Dev, Gaithersburg, MD USA

[6] AstraZeneca Pharmaceut LP, Oncol Biometr, Gaithersburg, MD USA

[7] AstraZeneca Pharmaceut LP, Oncol R&D, Late Dev, Cambridge, England

[8] Univ Calif Davis, Sacramento, CA 95817 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

185TiP

引用

页码：S798 / S798

页数：1